肝癌分子靶向药物耐药机制及其应对策略研究进展  

Research progress on the mechanism and response strategies of molecular targeted drug resistance in liver cancer

作　　者：宋枚芳 马路园 赵倩[2] 申川[1] 赵彩彦[1] Song Meifang;Ma Luyuan;Zhao Qian;Shen Chuan;Zhao Caiyan(Department of Infectious Disease,the Third Hospital of Hebei Medical University,Shijiazhuang 050051,China;Quality Management and Control Office,the Third Hospital of Hebei Medical University,Shijiazhuang 050051,China)

机构地区：[1]河北医科大学第三医院感染科,石家庄050051 [2]河北医科大学第三医院质量管理与控制办公室,石家庄050051

出　　处：《中华肝脏病杂志》2023年第10期1108-1112,共5页Chinese Journal of Hepatology

基　　金：河北省感染性疾病临床医学研究中心创新能力提升项目(20577704D);河北省省级医学优秀人才项目;国家自然科学基金青年科学基金(81900536)。

摘　　要：分子靶向药物是治疗肝癌的药物之一,耐药是影响治疗效果的主要因素。现从药物摄入减少及外排增加、DNA损伤修复能力增强、信号通路异常、缺氧、上皮细胞-间充质细胞转化和细胞自噬系统方面总结了其耐药机制,同时阐述了应对其耐药的有效策略,为临床更好治疗肝癌提供思路。Molecular targeted drugs are one of the treatments for hepatocellular carcinoma(HCC),the primary factor influencing their therapeutic efficacy is drug resistance.Diminished drug intake,greater efflux,improved DNA damage repair capacity,aberrant signal pathways,hypoxia,epithelial-mesenchymal cell transition,and the cellular autophagy system are summarized herein as aspects of the drug resistance mechanism.Simultaneously,effective strategies for addressing drug resistance are elaborated,providing ideas for better clinical treatment of HCC.

关 键 词：肝细胞癌 耐药机制 应对策略 

分 类 号：R735.7[医药卫生—肿瘤]